Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
PLoS One. 2009 Dec 14;4(12):e8275. doi: 10.1371/journal.pone.0008275.
Combination antiretroviral treatment (cART) has been very successful, especially among selected patients in clinical trials. The aim of this study was to describe outcomes of cART on the population level in a large national cohort.
Characteristics of participants of the Swiss HIV Cohort Study on stable cART at two semiannual visits in 2007 were analyzed with respect to era of treatment initiation, number of previous virologically failed regimens and self reported adherence. Starting ART in the mono/dual era before HIV-1 RNA assays became available was counted as one failed regimen. Logistic regression was used to identify risk factors for virological failure between the two consecutive visits.
Of 4541 patients 31.2% and 68.8% had initiated therapy in the mono/dual and cART era, respectively, and been on treatment for a median of 11.7 vs. 5.7 years. At visit 1 in 2007, the mean number of previous failed regimens was 3.2 vs. 0.5 and the viral load was undetectable (<50 copies/ml) in 84.6% vs. 89.1% of the participants, respectively. Adjusted odds ratios of a detectable viral load at visit 2 for participants from the mono/dual era with a history of 2 and 3, 4, >4 previous failures compared to 1 were 0.9 (95% CI 0.4-1.7), 0.8 (0.4-1.6), 1.6 (0.8-3.2), 3.3 (1.7-6.6) respectively, and 2.3 (1.1-4.8) for >2 missed cART doses during the last month, compared to perfect adherence. From the cART era, odds ratios with a history of 1, 2 and >2 previous failures compared to none were 1.8 (95% CI 1.3-2.5), 2.8 (1.7-4.5) and 7.8 (4.5-13.5), respectively, and 2.8 (1.6-4.8) for >2 missed cART doses during the last month, compared to perfect adherence.
A higher number of previous virologically failed regimens, and imperfect adherence to therapy were independent predictors of imminent virological failure.
联合抗逆转录病毒治疗(cART)非常成功,尤其是在临床试验中的选定患者中。本研究的目的是描述大型全国队列中人群中 cART 的结果。
分析了 2007 年两次半年期瑞士艾滋病毒队列研究中稳定接受 cART 的参与者的特征,包括治疗开始时的时代、以前失败的方案数量和自我报告的依从性。在 HIV-1 RNA 检测可用之前的单/双药时代开始接受 ART 被视为一种失败的方案。使用逻辑回归确定两次连续就诊之间病毒学失败的危险因素。
在 4541 名患者中,分别有 31.2%和 68.8%在单/双药和 cART 时代开始治疗,分别接受治疗的中位数为 11.7 年和 5.7 年。在 2007 年第一次就诊时,以前失败方案的平均数量分别为 3.2 个和 0.5 个,参与者的病毒载量分别为 84.6%和 89.1%不可检测(<50 拷贝/ml)。与 1 个失败相比,单/双药时代有 2 个和 3 个、4 个、>4 个既往失败史的参与者在第 2 次就诊时检测到病毒载量的调整优势比(95%CI)分别为 0.9(0.4-1.7)、0.8(0.4-1.6)、1.6(0.8-3.2)、3.3(1.7-6.6)和 2.3(1.1-4.8),而最近一个月漏服 cART 剂量>2 次的参与者则分别为 2.3(1.1-4.8)。与无既往失败史相比,来自 cART 时代的参与者的优势比分别为 1 个、2 个和>2 个失败史为 1.8(95%CI 1.3-2.5)、2.8(1.7-4.5)和 7.8(4.5-13.5),漏服 cART 剂量>2 次的参与者则分别为 2.8(1.6-4.8)。
以前失败的方案数量较多,以及治疗依从性不完美是病毒学失败的独立预测因素。